Effects of Nicotine on the Translation of Stem Cell Therapy

Abstract

Although stem cell therapy has tremendous therapeutic potential, clinical translation of stem cell therapy has yet to be fully realized. Recently, patient comorbidities and lifestyle choices have emerged to be important factors in the efficacy of stem cell therapy. Tobacco usage is an important risk factor for numerous diseases, and nicotine exposure specifically has become increasing more prevalent with the rising use of electronic cigarettes. This review describes the effects of nicotine exposure on the function of various stem cells. We place emphasis on the differential effects of nicotine exposure in vitro and as well as in preclinical models. Further research on the effects of nicotine on stem cells will deepen our understanding of how lifestyle choices can impact the outcome of stem cell therapies.

Keywords::

• electronic cigarettes
• nicotine
• stem cell therapy
• tobacco

Acknowledgments

We acknowledge A Muller from the Stanford Cardiovascular Institute for language editing assistance.

Financial & competing interests disclosure

This work was supported in part by grants to NFH from the US NIH (R01 HL127113 and R01 HL142718), and the US Department of Veterans Affairs (1I01BX002310 and 1I01BX004259). AHPC was supported by a postdoctoral fellowship from the Tobacco Related Disease Research Program (T30FT0860). This publication was made possible by a grant from the US FDA, which supports the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (U01FD005978). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the HHS or FDA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported in part by grants to NFH from the US NIH (R01 HL127113 and R01 HL142718), and the US Department of Veterans Affairs (1I01BX002310 and 1I01BX004259). AHPC was supported by a postdoctoral fellowship from the Tobacco Related Disease Research Program (T30FT0860). This publication was made possible by a grant from the US FDA, which supports the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (U01FD005978). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the HHS or FDA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.